Search results for: Genetic
Filter search results
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
…numerous other genetically-based conditions. Individually, each treatment will be extremely expensive, and in the aggregate their costs are projected to have a substantial impact on the affordability of health care….
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…Hughes (Avalere Health LLC). Panellists: Adrian Towse (OHE), Sachin Kamal-Bahl (Pfizer), Alastair Kent (Genetic Alliance UK). Maintaining patient focus in healthcare decision-making is a universally-accepted approach to ensuring positive outcomes….
Economic Aspects of Non-Hodgkin’s Lymphoma
1 July 1998
…for NHL have been proffered and some links established (for example, the existence of infectious agents such as HIV, and genetic susceptibility), there is still much uncertainty surrounding all the…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…this publication. 1. Health care will be radically transformed as “precision” medicines plug into the specific genetic makeup of both patients and diseases, paired with increasingly powerful and convenient diagnostics….
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
In November, ISPOR Europe was hosted in person for the first time since 2019 at the Austria Centre, Vienna. In front of a full theatre, OHE’s Professor Adrian Towse introduced…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
Gene therapies directly address the underlying cause of disease, and many of them offer short-term treatment regimens. As a result, they could bring transformative benefits to patients by halting disease…
The Promise of Gene Therapies: Are We Ready?
1 April 2021
In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and value. Special attention is…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The purpose of this OHE…